In recent years, extracellular vesicles (EVs) have emerged as promising vehicles for drug delivery in various diseases, including bladder cancer. At Alfa Cytology, we have established a dedicated platform to help you develop EV drug delivery system in bladder cancer.

Introduction to EVs-Based Drug Delivery System

EVs are small lipid membrane-bound vesicles released by cells. They consist of microvesicles, exosomes, and apoptotic bodies, each with distinct characteristics and cellular origin. EVs have gained significant attention as potential carriers for delivering therapeutic agents due to their unique properties. They offer advantages such as biocompatibility, ability for targeted delivery, and protection of cargo from degradation.

Fig 1. Type of extracellular vesicle.

Bladder cancer is a complex disease characterized by uncontrolled cell growth in the urinary bladder. Conventional treatment modalities, including surgery, chemotherapy, and radiation therapy, have limitations such as systemic toxicity and low selectivity for cancer cells. The development of a targeted drug delivery system using EVs holds great promise for improving the efficacy and safety of bladder cancer therapy.

Fig 2. Composition of extracellular vesicle-based delivery systems.

Our Services

At Alfa Cytology, we offer comprehensive services for the development of EVs-based DDS for bladder cancer therapy. Our expertise and state-of-the-art technologies enable us to provide tailored solutions to meet the specific needs of our clients.

• EVs Isolation and Purification
  Specializing in the isolation and purification of EVs from various sources, including cell culture media and body fluids, we employ advanced laboratory techniques and cutting-edge equipment to obtain EVs with high purity and yield. The isolation process ensures the removal of contaminants and other unwanted components, resulting in EVs that are suitable for downstream applications.
• Cargo Loading and Modification
  We have developed innovative methods for encapsulating a wide range of therapeutic agents, including small molecules, nucleic acids, and proteins, into EVs. Furthermore, we offer customization options for EV surface modification to enhance their targeting capabilities.
• In vitro and In vivo Evaluation
  Our advanced imaging techniques and molecular biology assays allow us to accurately analyse the interaction between EVs and target cells. In vivo studies are performed using preclinical models of bladder cancer to evaluate the pharmacokinetics, biodistribution, and therapeutic efficacy of EV-based drug delivery systems.

Our Service Process

Contact Us

Alfa Cytology is committed to advancing the field of extracellular vesicles-based drug delivery for bladder cancer. Our multidisciplinary team of experts is dedicated to providing innovative solutions and contributing to the development of effective therapies. If you would like to learn more about our services or discuss potential collaborations, please contact us today to explore the possibilities of this innovative approach in cancer therapy.

• Cell Membranes-Based Delivery System Development
• Chitosan-Based Delivery System Development
• Gel-Based Delivery System Development
• Liposomal Delivery System Development
• Metal Nanoparticles-Based Delivery System Development
• Microemulsion-Based Delivery System Development
• MSNP-Based Delivery System Development
• Polymeric Micelles Delivery System Development
• Urease-Powered Nanomotor Delivery System Development